Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700071 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL4091794 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL2728508 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL21848352 | 0.88 | MEN1 (0.61) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL31544172 | 0.88 | MEN1 (0.61) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL21848350 | 0.88 | MEN1 (0.61) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL10578571 | 0.85 | MEN1 (0.67) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL10578566 | 0.85 | MEN1 (0.67) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL27530711 | 0.81 | MEN1 (0.53) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL7826640 | 0.81 | MEN1 (0.53) | MEN1KMT2ACYP1A2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016952-A1 | SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016952-A1 | SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-9145411-B2 | Substituted amino-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145411-B2 | Substituted amino-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-09-29 | — | — | US | disclosed |
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2014022728-A1 | SUBSTITUTED 5 - (QUINAZOLIN - 2 - YL) PYRIMIDIN- 2 -AMINE DERIVATIVES USEFUL AS PI3K/MTOR INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS, INC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140038952-A1 | Substituted Amino-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038952-A1 | Substituted Amino-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012058671-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016952-A1 | SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, AKT3 | MEN1 4217/4885KMT2A 1856/4885CYP1A2 1802/4885 |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | MEN1 3430/4885KMT2A 1584/4885CYP1A2 1891/4885 |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | MEN1 3430/4885KMT2A 1584/4885CYP1A2 1891/4885 |
| US-20140038952-A1 | Substituted Amino-Pyrimidine Derivatives | MTOR, PIK3CA, AKT3 | MEN1 4217/4885KMT2A 1856/4885CYP1A2 1802/4885 |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | MEN1 3430/4885KMT2A 1584/4885CYP1A2 1891/4885 |
| US-20120129851-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | MEN1 3430/4885KMT2A 1584/4885CYP1A2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.